CoChat
Sign Up
Cited by 906Fibroblast Growth Factor ResearchConnective Tissue Growth Factor ResearchCongenital limb and hand anomalies

The DOI matches its Crossref record; 756 of the 760 references it cites were found in a registry or an index.

FGF/FGFR signaling in health and disease

Open access
Xie, Yangli, Su, Nan, Yang, Jing, Tan, Qiaoyan, Huang, Shuo, Jin, Min, Ni, Zhenhong, Zhang, Bin, Zhang, Dali, Luo, Fengtao, Chen, Hangang, Sun, Xianding, Feng, Jian Q., Qi, Huabing, Chen, Lin·2020·Signal Transduction and Targeted Therapy
DOI 10.1038/s41392-020-00222-7PMC PMC7468161
Open this paper in CoChat — free accountOpen PDF

Abstract

Growing evidences suggest that the fibroblast growth factor/FGF receptor (FGF/FGFR) signaling has crucial roles in a multitude of processes during embryonic development and adult homeostasis by regulating cellular lineage commitment, differentiation, proliferation, and apoptosis of various types of cells. In this review, we provide a comprehensive overview of the current understanding of FGF signaling and its roles in organ development, injury repair, and the pathophysiology of spectrum of diseases, which is a consequence of FGF signaling dysregulation, including cancers and chronic kidney disease (CKD). In this context, the agonists and antagonists for FGF-FGFRs might have therapeutic benefits in multiple systems.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-020-00222-7

Cites

756 of 756 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Summary of the main roles of FGF/FGFR signaling in organ development, metabolism, and disease. FGF/FGFR signaling participates in the development of almost all organ such as lung, heart, urinary system, brain, skeleton, muscle, and skin/appendage, as well as angiogenesis and lymphangiogenesis. FGFs/FGFRs also have important effects on tissue repair, regeneration, and inflammation. Furthermore, endocrine FGFs play critical roles in metabolism by regulating kidney, liver, brain, intestine, and adipose tissue. The malfunctions of FGF/FGFR signaling lead to multiple kinds of diseases, such as genetic diseases, cancer, COPD, and CKD. The roles of FGF signaling in appendage development, such as epidermis, hair, and glands, and so on, is not mentioned in this review. ACH achondroplasia, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, PS Pfeiffer syndrome, RDS respiratory distress syndrome, EndMT endothelial-to-mesenchymal transition
Fig. 1 Summary of the main roles of FGF/FGFR signaling in organ development, metabolism, and disease. FGF/FGFR signaling participates in the development of almost all organ such as lung, heart, urinary system, brain, skeleton, muscle, and skin/appendage, as well as angiogenesis and lymphangiogenesis. FGFs/FGFRs also have important effects on tissue repair, regeneration, and inflammation. Furthermore, endocrine FGFs play critical roles in metabolism by regulating kidney, liver, brain, intestine, and adipose tissue. The malfunctions of FGF/FGFR signaling lead to multiple kinds of diseases, such as genetic diseases, cancer, COPD, and CKD. The roles of FGF signaling in appendage development, such as epidermis, hair, and glands, and so on, is not mentioned in this review. ACH achondroplasia, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, PS Pfeiffer syndrome, RDS respiratory distress syndrome, EndMT endothelial-to-mesenchymal transitionCC BY · PubMed Central
Fig. 2 The classical FGF/FGFR pathways. Binding of appropriate growth factors to receptors triggers the conformational changes of FGFRs, resulting in dimerization and activation of FGFRs. Activated FGFRs phosphorylate FRS2a and FRS2a binds to SH2 domain-containing adaptor Grb2. Grb2 will subsequently bind to SOS, GAB1, and Cbl through its SH3 domain to activate Ras/Raf/MAPKs, including ERK MAPK, p38 MAPK, and JNK MAPK. The activated FGFRs also activate phosphatidylinositol (PI)-3 kinase and STAT. FGFRs recruit and phosphorylate PLCγ. Among the members of the FGF synexpression group, SEF and XFLRT3 are transmembrane proteins and can interact directly with FGFRs. SEF functions as a negative regulator by affecting the phosphorylation of the MAPK ERK cascade. XFLRT3 forms a complex with FGF receptors and enhances FGF/FGFR signaling. Spry acts at the level of Grb2 and/or the level of Raf to attenuate FGF/FGFR signaling. MKP3 negatively regulates FGF/FGFR signaling by dephosphorylating the activated ERK. FRS2α FGFR substrate 2α, GAB1 GRB2 associated binding protein 1, GRB2 growth factor receptor-bound 2, PKC protein kinase C, SOS son of sevenless
Fig. 2 The classical FGF/FGFR pathways. Binding of appropriate growth factors to receptors triggers the conformational changes of FGFRs, resulting in dimerization and activation of FGFRs. Activated FGFRs phosphorylate FRS2a and FRS2a binds to SH2 domain-containing adaptor Grb2. Grb2 will subsequently bind to SOS, GAB1, and Cbl through its SH3 domain to activate Ras/Raf/MAPKs, including ERK MAPK, p38 MAPK, and JNK MAPK. The activated FGFRs also activate phosphatidylinositol (PI)-3 kinase and STAT. FGFRs recruit and phosphorylate PLCγ. Among the members of the FGF synexpression group, SEF and XFLRT3 are transmembrane proteins and can interact directly with FGFRs. SEF functions as a negative regulator by affecting the phosphorylation of the MAPK ERK cascade. XFLRT3 forms a complex with FGF receptors and enhances FGF/FGFR signaling. Spry acts at the level of Grb2 and/or the level of Raf to attenuate FGF/FGFR signaling. MKP3 negatively regulates FGF/FGFR signaling by dephosphorylating the activated ERK. FRS2α FGFR substrate 2α, GAB1 GRB2 associated binding protein 1, GRB2 growth factor receptor-bound 2, PKC protein kinase C, SOS son of sevenlessCC BY · PubMed Central
Fig. 3 The regulation of FGF15/19 on energy metabolism. FGF15/19 regulates energy metabolism both peripherally and centrally. In the liver, FGF15/19 inhibits BA production and promotes gallbladder filling. As for lipid and glucose metabolism, FGF15/19 improves glycogen synthesis, but suppresses lipogenesis and gluconeogenesis. In the adipose tissue, FGF15/19 promotes energy expenditure and fatty acid oxidation. In the brain, FGF15/19 promotes the expression of CRF in the hypothalamus and stimulates sympathetic nerve activity, and then increases energy expenditure in the adipose tissue. Furthermore, FGF15/19 promotes peripheral insulin sensitivity and glucose metabolism by repressing HPA axis and AGRP/NPY neuron activity. AGRP agouti-related protein, BA bile acid, HPA hypothalamic-pituitary-adrenal, NPY neuropeptide Y
Fig. 3 The regulation of FGF15/19 on energy metabolism. FGF15/19 regulates energy metabolism both peripherally and centrally. In the liver, FGF15/19 inhibits BA production and promotes gallbladder filling. As for lipid and glucose metabolism, FGF15/19 improves glycogen synthesis, but suppresses lipogenesis and gluconeogenesis. In the adipose tissue, FGF15/19 promotes energy expenditure and fatty acid oxidation. In the brain, FGF15/19 promotes the expression of CRF in the hypothalamus and stimulates sympathetic nerve activity, and then increases energy expenditure in the adipose tissue. Furthermore, FGF15/19 promotes peripheral insulin sensitivity and glucose metabolism by repressing HPA axis and AGRP/NPY neuron activity. AGRP agouti-related protein, BA bile acid, HPA hypothalamic-pituitary-adrenal, NPY neuropeptide YCC BY · PubMed Central
Fig. 4 The regulation of FGF21 on energy metabolism. FGF21 regulates energy metabolism in peripheral and central manners. In the liver, FGF21 promotes gluconeogenesis and lipid oxidation, and thus improves ketogenesis and insulin sensitivity. In the adipose tissue, FGF21 simulates glucose uptake in both WAT and BAT and induces WAT browning, as well as promotes energy expenditure, while FGF21 inhibits lipolysis. In the brain, FGF21 stimulates the HPA axis, thus contributing to corticosterone release and ultimately promoting gluconeogenesis in the liver. Furthermore, FGF21 improves CRF expression in the hypothalamus and stimulates sympathetic nerve activity, and then promotes energy expenditure in BAT. BAT brown adipose tissue, CRF corticotropin-releasing factor, HPA hypothalamic-pituitary-adrenal, WAT white adipose tissue
Fig. 4 The regulation of FGF21 on energy metabolism. FGF21 regulates energy metabolism in peripheral and central manners. In the liver, FGF21 promotes gluconeogenesis and lipid oxidation, and thus improves ketogenesis and insulin sensitivity. In the adipose tissue, FGF21 simulates glucose uptake in both WAT and BAT and induces WAT browning, as well as promotes energy expenditure, while FGF21 inhibits lipolysis. In the brain, FGF21 stimulates the HPA axis, thus contributing to corticosterone release and ultimately promoting gluconeogenesis in the liver. Furthermore, FGF21 improves CRF expression in the hypothalamus and stimulates sympathetic nerve activity, and then promotes energy expenditure in BAT. BAT brown adipose tissue, CRF corticotropin-releasing factor, HPA hypothalamic-pituitary-adrenal, WAT white adipose tissueCC BY · PubMed Central
Fig. 5 The regulation of FGF23 and its effect on phosphate homeostasis. The bone-derived FGF23 is regulated by several factors such as iron, phosphate, and 1,25(OH)2D3 and PTH in blood, as well as DMP1, PHEX, and FGFR1 in the bone. FGF23 downregulates serum phosphate. In the kidney, FGF23 reduces 1,25(OH)2D3 level and inhibits renal phosphate resorption by inhibiting the expression of NaPi-2a/2c. In the intestine, FGF23 inhibits phosphate absorption by reducing NaPi-2b expression or indirectly suppressing 1,25(OH)2D3. In the parathyroid, FGF23 inhibits PTH synthesis and secretion, and then contributes to its own negative feedback regulation. 1,25VD3 1,25(OH)2D3, NaPi-2 type IIa sodium-phosphate co-transporter, PTH parathyroid hormone
Fig. 5 The regulation of FGF23 and its effect on phosphate homeostasis. The bone-derived FGF23 is regulated by several factors such as iron, phosphate, and 1,25(OH)2D3 and PTH in blood, as well as DMP1, PHEX, and FGFR1 in the bone. FGF23 downregulates serum phosphate. In the kidney, FGF23 reduces 1,25(OH)2D3 level and inhibits renal phosphate resorption by inhibiting the expression of NaPi-2a/2c. In the intestine, FGF23 inhibits phosphate absorption by reducing NaPi-2b expression or indirectly suppressing 1,25(OH)2D3. In the parathyroid, FGF23 inhibits PTH synthesis and secretion, and then contributes to its own negative feedback regulation. 1,25VD3 1,25(OH)2D3, NaPi-2 type IIa sodium-phosphate co-transporter, PTH parathyroid hormoneCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

5 retracted

Show all 760 references

Research works printed but not linked: 1

  1. Wang, Y. & Becker, D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat. Med. 3, 887–893 (1997). · DOI

Cited by

Sorted by citations

Items 301–400 of 906

Related

See all

Metadata

Authors
Xie, Y., Su, N., Yang, J., Tan, Q., Huang, S., Jin, M., Ni, Z., Zhang, B., Zhang, D., Luo, F., Chen, H., Sun, X., Feng, J. Q., Qi, H., & Chen, L.
Affiliations
  • Army Medical University (CN)
  • Texas A&M University (US)
Corresponding author
Xie, Yangli
ORCID
Venue
Signal Transduction and Targeted Therapy
Publisher
Springer Science and Business Media LLC
Published
2020-09-02
Volume
5
Issue
1
Pages
181-181
ISSN
2059-3635 (ISSN-L)
DOI
10.1038/s41392-020-00222-7
PMC
PMC7468161
OpenAlex
W3082979654
Cited by
904
References
760
Citations by year
2026: 148 · 2025: 190 · 2024: 205 · 2023: 151 · 2022: 124 · 2021: 76 · 2020: 9
FWCI
8.62
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (81772306, IRT1216, 81991513, 81530071, 2018YFA0800802, 81721001)
  • National Key Research and Development Program of China (2018YFA0800802)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Connective Tissue Growth Factor Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Developmental Biology › Congenital limb and hand anomalies
Keywords
fibroblast growth factor, fibroblast growth factor receptor, FGF/FGFR signaling, organogenesis, tissue repair, cancer, chronic kidney disease, therapeutic target, cell differentiation, apoptosis
MeSH terms
Cell Differentiation, Fibroblast Growth Factors, Homeostasis, Humans, Neoplasms, Signal Transduction, Apoptosis, Receptors, Fibroblast Growth Factor, Embryonic Development, Cell Proliferation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review